On August 6, SKB BIO rose 3.4% in regular trading, trading at 509.5 HKD/share, with turnover of HKD 83.28 million.

On the news front, the company announced on August 5 that its board will convene on August 17 to review and approve interim results for the six months ended June 30, fueling market expectations for earnings delivery. Goldman Sachs and JPMorgan previously raised their target prices to HKD 582.95 and HKD 648 respectively, both maintaining buy ratings. Goldman Sachs cited positive clinical results for sac-TMT in first-line NSCLC treatment, raising the Lung06 success probability from 81% to 90%.

Multiple recent pipeline milestones further support sentiment: the company's TROP2 ADC sacituzumab tirumotecan received NMPA acceptance for its sixth indication in triple-negative breast cancer on July 30, while novel dual-payload ADC SKB565 obtained IND approval for advanced solid tumors on July 27. Additionally, Merck initiated a Phase II trial combining sac-TMT with its PD-1/VEGF bispecific antibody MK-2010.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)